Trial data underpins FDA approval of omalizumab for food allergy
Today’s Food and Drug Administration approval of a supplemental biologics license for the monoclonal antibody omalizumab (Xolair) highlights the vital role of the National Institutes of Health-supported research that underpins the FDA decision.
Facebook Comments
https://www.sarkaridoctor.com/wp-content/uploads/2022/01/logo@2xx.png00aajahttps://www.sarkaridoctor.com/wp-content/uploads/2022/01/logo@2xx.pngaaja2024-02-17 12:05:232024-02-17 12:05:23Trial data underpins FDA approval of omalizumab for food allergy
Hitchhiking cancer vaccine makes progress in the clinic